Skip to main content

Research Repository

Advanced Search

Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays

Harris, Leanne F.; O'Donnell, James S.; O'Brien, Aoife; Killard, Anthony; Castro-L�pez, Vanessa

Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays Thumbnail


Authors

Leanne F. Harris

James S. O'Donnell

Aoife O'Brien

Vanessa Castro-L�pez



Abstract

Introduction: Fast and accurate monitoring is crucial in the successful regulation of coagulation therapy. For the treatment of venous thromboembolism, both unfractionated heparin (UFH) and low molecular weight heparins (LMWHs) are commonly administered. The chromogenic anti-factor Xa (FXa) assay is currently considered the 'gold standard' assay for monitoring LMWH. However different commercial chromogenic methods often differ when tested with the same samples. Fluorogenic anti-FXa assays have the potential to offer greater benefits over chromogenic assays in terms of greater specificity, sensitivity and they are not so influenced by sample opacity or turbidity. Materials and methods: Commercial plasmas were spiked with pharmacologically relevant concentrations (0-1 U/ml) of UFH, enoxaparin, and tinzaparin. The fluorogenic assay was carried out using previously optimized concentrations of 12 nM FXa and 2.7 μM fluorogenic substrate, in addition to 6 μl of 100 mM CaCl 2 and 44 μl of plasma. The Biophen® and Coamatic chromogenic assays were carried out according to the manufacturer's instructions. Reaction rates and endpoint values were analyzed and statistical analysis by means of one-way analysis of variance (ANOVA) was performed. Results: The fluorogenic anti-FXa assay was found to have the broadest therapeutic range of 0-1 U/ml with CVs of < 5% for UFH and tinzaparin and CVs < 9% for enoxaparin. Despite their limited measuring range, good assay reproducibility was observed with both chromogenic kits. Conclusions: This study indicated that the fluorogenic assay is the most sensitive assay with the broadest dynamic range for monitoring LMWH therapy when compared with standard chromogenic assays. © 2011 Elsevier Ltd. All rights reserved.

Citation

O'Donnell, J. S., Harris, L. F., O'Brien, A., Castro-López, V., & Killard, A. (2011). Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays. Thrombosis Research, 128(6), 166-170. https://doi.org/10.1016/j.thromres.2011.08.002

Journal Article Type Article
Publication Date Dec 1, 2011
Deposit Date Sep 13, 2011
Publicly Available Date Nov 15, 2016
Journal Thrombosis Research
Print ISSN 0049-3848
Electronic ISSN 1879-2472
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 128
Issue 6
Pages 166-170
DOI https://doi.org/10.1016/j.thromres.2011.08.002
Keywords Factor Xa, fluorogenic, chromogenic, low molecular weight heparin
Public URL https://uwe-repository.worktribe.com/output/968844
Publisher URL http://dx.doi.org/10.1016/j.thromres.2011.08.002

Files


Harrisetal.Thrombosis_Research.doc (91 Kb)
Document





You might also like



Downloadable Citations